Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets

Ahmedabad, India, 26 July, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has received final approval from the United States Food and Drug Administration (USFDA) to market Bisoprolol Fumarate Tablets USP 5 mg and 10 mg. USRLD: Zebeta.

Bisoprolol Fumarate Tablets are used to treat high blood pressure. They can be used alone or in combination with other high blood pressure medications to lower blood pressure. The drug will be manufactured at the group's formulation manufacturing facility at, SEZ, Ahmedabad, India and will be distributed by Viona Pharmaceuticals Inc.

Bisoprolol Fumarate Tablets had annual sales of USD 30 million in the United States according to IQVIA data (IQVIA MAT May 2022).

The group now has 318 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 31st March 2022)*

****

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878